Farmas USA

https://inbestia.com/analisis/vuelve-el-miedo-a-pesar-de-estar-casi-en-maximos-anuales

International FX Perspective: Are U.S. Stocks Still Overbought?

Bollinger Bands, as a basic statistical tool, can be used to judge whether U.S. stocks are in over-bought or over-sold territory.

The Bollinger Bands for SPY and QQQ currently demonstrate that U.S. stocks are possibly going to find short-term support, albeit with some potentially more modest weakening in the near term.

The Bollinger Bands can be recalculated in foreign-currency terms, to achieve a more comprehensive, global short-term perspective on U.S. stock prices.

Both the domestic and foreign-currency bands now suggest U.S. stocks are more fairly priced, but a further unwind in important currency pairs such as the USD/JPY pair could produce a far more damaging correction.

Investing in U.S. stocks could currently be viewed as being more risky than it has been for many years, from both long-term market-value-to-GDP and foreign-currency (using USD/JPY as an example) viewpoints.

https://seekingalpha.com/article/4210297-international-fx-perspective-u-s-stocks-still-overbought

Catalizadores este mes

AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) will be presenting additional data from its Phase 2 results from its tivozanib and nivolumab trial at the European Society of Medical Oncology (ESMO) on October 22. The study is looking to treat advanced renal cell carcinoma.

Mirati Therapeutics Inc. (NASDAQ: MRTX) will be presenting an update from its Phase 2 study of sitravatinib for the treatment of non-small cell lung cancer at the ESMO on October 22.

Neon Therapeutics Inc. (NASDAQ: NTGN) is another presenter at the ESMO. The company will be presenting updated data from NT-001, its ongoing Phase 1b clinical trial in metastatic melanoma, lung cancer and bladder cancer.

Tricida Inc. (NASDAQ: TCDA) will present Phase 3 data from its TRCA-301 clinical trial of TRC101 designed to treat metabolic acidosis in patients with chronic kidney disease. The data will be presented at Kidney Week 2018, the annual meeting of the American Society of Nephrology on October 23 to 28.

TG Therapeutics Inc. (NASDAQ: TGTX) has final Phase 2 data from its trial of ublituximab (TG-1101) in relapsing forms of multiple sclerosis in October. The company will make an oral presentation at the upcoming 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which will be held on October 10 to 12.

RegenXBio Inc. (NASDAQ: RGNX) is expected to present Phase 1 clinical trial data evaluating RGX-314 for the treatment of wet age-related macular degeneration later this month. On October 26, the firm will present the interim results at the American Academy of Ophthalmology 2018 Annual Meeting.

Merus N.V. (NASDAQ: MRUS) has Phase 1/2 data for MCLA-128 due at the ESMO with other cohort data due in the fourth quarter of this year. MCLA-128 has a few indications to treat gastric, ovarian, endometrial and non-small cell lung cancer.

Merck & Co. Inc. (NYSE: MRK) has a PDUFA target action date of October 6, for its Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant), the company’s 9-valent HPV vaccine. The application is seeking approval for an expanded age indication for Gardasil 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine HPV types covered by the vaccine.

Trevena Inc. (NASDAQ: TRVN) previously announced that the FDA has scheduled a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee on October 11 to discuss the safety and efficacy of oliceridine injection for the management of moderate to severe acute pain. The company has a PDUFA target date of November 2.

PRESENTS NEW ANALYSES SUPPORTING THE USE OF TRULANCE® (PLECANATIDE)

IN TWO PATIENT POPULATIONS AT THE AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG) 

https://ir.synergypharma.com/press-releases/detail/1878

+20% $PEIX

OFF TOPIC

PEIX

Fuera 4K cromos a 2.20  -600$   sigo dentro con 3K a 2.36

TGTX

Dentro el viernes a 5.39  1K cromos

In 4k cromos a 5,35 TGTX con intención, a ser posible, de aguantarlos hasta el 10-12 de las conferencias.

In 1k cromos 20,18 AMRN, a romper los 20,50 vamosssssss

ACAD, velas 30 min, HCH … si rompe, proyección máxima en base de canal por loa 19medios … 

edito: AMRN cagadica, me espero a ver … 

edito: GERN in 10k cromos a 1,84 .. .acabo de ver que esta haciendo un canal ascendente en verlas 1h

edito: uy, se acabo el rebote? me salgo de GERN en tablas … mantengo TGTX y AMARIN porque no me queda otra

edito: ahora cuando le doy a imprimir pantallazo me sale una tocho imagen con los dos monitores juntos, tengo que recortar y bla, bla ,bla … no puedo hacer eso mientras tradeo. :(

Jjjjj son muchas cosas jjj numeros líneas y encima escribir en el foro con pantallazo se agradece macho se agradece joder